These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187 [TBL] [Abstract][Full Text] [Related]
63. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. Ananworanich J; Siangphoe U; Mahanontharit A; Hill A; Hirschel B; Ruxrungtham K Antivir Ther; 2004 Dec; 9(6):1035-6. PubMed ID: 15651763 [No Abstract] [Full Text] [Related]
64. Better lipid profile for Invirase. AIDS Patient Care STDS; 2006 Dec; 20(12):888. PubMed ID: 17216875 [No Abstract] [Full Text] [Related]
65. Fortovase is preferred treatment. AIDS Patient Care STDS; 1998 Jun; 12(6):495. PubMed ID: 11362001 [No Abstract] [Full Text] [Related]
66. Patients sought for ACTU studies that will help answer questions about drugs. Fac Notes (New Orleans La); 1998; 10(6):6. PubMed ID: 11366145 [TBL] [Abstract][Full Text] [Related]
67. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response. Nieuwkerk P; Gisolf E; Sprangers M; Danner S; Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422 [TBL] [Abstract][Full Text] [Related]
68. First clinical data presented on FortovAse. AIDS Patient Care STDS; 1997 Dec; 11(6):455. PubMed ID: 11361868 [No Abstract] [Full Text] [Related]
69. Invirase program expands. AIDS Patient Care; 1995 Dec; 9(6):305. PubMed ID: 11361444 [No Abstract] [Full Text] [Related]
70. Saquinavir. Porche DJ J Assoc Nurses AIDS Care; 1996; 7(4):61-4. PubMed ID: 8875367 [No Abstract] [Full Text] [Related]
71. Saquinavir: newest weapon in the antiviral arsenal. MacDougall DS J Int Assoc Physicians AIDS Care; 1996 Feb; 2(2):25-31. PubMed ID: 11363336 [TBL] [Abstract][Full Text] [Related]
72. Invirase remains available. AIDS Patient Care STDS; 1998 Oct; 12(10):802-3. PubMed ID: 11362029 [No Abstract] [Full Text] [Related]
73. Medical marijuana study in San Francisco: pays $1000, 25 days in hospital. AIDS Treat News; 1998 Jun; (No 296):3-4. PubMed ID: 11365468 [TBL] [Abstract][Full Text] [Related]
74. [HIV protease inhibitors]. Silbermann B; Yousry C; Salmon-Céron D Ann Med Interne (Paris); 2000 Jun; 151(4):268-77. PubMed ID: 10922954 [No Abstract] [Full Text] [Related]
75. Invirase replaced by Fortovase. Am J Nurs; 1998 Feb; 98(2):24. PubMed ID: 9473980 [No Abstract] [Full Text] [Related]
76. A reportback from the Third National Conference on Women and HIV. Russell A Crit Path AIDS Proj; 1997; (No 32):25-7. PubMed ID: 11364436 [TBL] [Abstract][Full Text] [Related]
77. University of Washington AIDS Clinical Trials Unit: list of studies - July 1998. STEP Perspect; 1998; 98(3):21. PubMed ID: 11365826 [TBL] [Abstract][Full Text] [Related]
78. Can inhibition of proteasomes or NF-kappaB help control idiopathic nephrotic syndrome? Wenderfer SE Nephrol Dial Transplant; 2012 May; 27(5):1698-701. PubMed ID: 22547747 [No Abstract] [Full Text] [Related]
79. Inclusion of women in HIV research and clinical trials. Johnston CD; O'Brien R; Côté HCF AIDS; 2023 May; 37(6):995-997. PubMed ID: 37017020 [No Abstract] [Full Text] [Related]